Prostate cancer perspectives after chaarted: Optimizing treatment sequence

详细信息    查看全文

• 作者：Sergio Vá ; zquez Esté ; vez^a ; ^{sergio.vazquez.Estevez@sergas.es" class="auth_mail" title="E-mail the corresponding author} ; Urbano Anido Herranz^b ; Ovidio Ferná ; ndez Calvo^c ; Francisco Javier Afonso Afonso^d ; Lucí ; a Santomé ; Couto^e ; Martí ; n Lá ; zaro Quintela^f ; Luis Leó ; n Mateos^g ; Sonia Maciá ; Escalante^h ; ^{sonia.macia@pivotal.es" class="auth_mail" title="E-mail the corresponding author}
• 关键词：CHAARTED ; Docetaxel ; Prostate cancer ; Immunotherapy ; Alpha-emitters ; Hormonotherapy
• 刊名：Critical Reviews in Oncology and Hematology
• 出版年：2016
• 出版时间：November 2016
• 年：2016
• 卷：107
• 期：Complete
• 页码：119-127
• 全文大小：643 K

文摘

Prostate cancer is the most frequent cancer amongst men. Until recently, only two therapeutic options, initial androgen-deprivation therapy in patients without castration-resistant prostate cancer, with addition of docetaxel when the disease becomes castration-resistant, were considered as standard. In the last years, new drugs (abiraterone, enzalutamide, Ra-223, Sipuleucel) have been developed for prostate cancer treatment with important advantages in safety and efficacy. Results from the recent Chaarted study, in patients that received docetaxel for the hormone sensitive disease, have contributed to change the initial treatment approach in metastatic prostate cancer, in order to adapt the best sequence for each patient. Those results have been supported by the Stampede trial. Stampede survival data showed not only a benefit in overall survival of adding docetaxel initially, but also a prolonged time to first skeletal related event. Now it is discussed in which setting the available drugs should be administered. This review article summarizes the treatment options for patients treated with docetaxel initially for hormone sensitive prostate cancer after developing progressive disease, and offers an algorithm proposal for treatment.